The loss, mutation, or functional defects in CXXC5 are associated with a range of hematopoietic disorders, including abnormalities in proliferation and differentiation, and some studies have identified CXXC5 as an essential effector to promote terminal differentiation of cancer cells in the treatment of APL with ATRA [29]. This evidence concerns the gene CXXC5 and cancer.